Original articleAlimentary tractEndoscopic Assessment and Treating to Target Increase the Likelihood of Mucosal Healing in Patients With Crohn’s Disease
Section snippets
Study Population
All medical records of consecutive patients referred to the Inflammatory Bowel Disease (IBD) center at the University of California San Diego (UCSD) between January 2011 and December 2012 were reviewed. The International Classification of Diseases, 9th revision, codes were used to identify all patients with a diagnosis of CD or regional enteritis who were referred to UCSD. The diagnosis of CD then was confirmed based on radiologic, endoscopic, and/or histologic evidence. Only patients with CD
Characteristics of the Population at Referral
Of 510 patients with CD seen at UCSD during the study period, 199 patients were referred to the IBD center, leading to 171 endoscopic procedures performed at the time of referral. A total of 110 patients had at least 2 consecutive endoscopic procedures performed during the study period. Among those 110 patients, 67 patients who had ulcers seen at the initial endoscopic procedure constituted the study population.
The baseline characteristics of these 67 patients are listed in Table 1. Of these
Discussion
This study specifically investigated the feasibility of a treat-to-target approach in patients with CD, in which the goal of medical therapy is endoscopic healing of the mucosa. In this retrospective cohort of patients with moderate to severe CD, we found that a high rate of MH can be achieved. The occurrence of MH during the study period was associated strongly with adjustment in medical therapy according to endoscopic findings.
MH is receiving increasing attention based on observations that
References (23)
Current directions in IBD therapy: what goals are feasible with biological modifiers?
Gastroenterology
(2008)- et al.
Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort
Gastroenterology
(2007) - et al.
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease
Gastroenterology
(2004) - et al.
Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn’s disease
Gastroenterology
(2010) - et al.
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial
Lancet
(2008) - et al.
Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn’s disease
Gastrointest Endosc
(2006) - et al.
Endoscopic monitoring of Crohn’s disease treatment: a prospective, randomized clinical trial. The Groupe d’Etudes Therapeutiques des Affections Inflammatoires Digestives
Gastroenterology
(1992) - et al.
Results of the 2nd part Scientific Workshop of the ECCO. II: measures and markers of prediction to achieve, detect, and monitor intestinal healing in inflammatory bowel disease
J Crohns Colitis
(2011) - et al.
Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial
Gastroenterology
(2007) - et al.
Deep remission: a new concept?
Dig Dis
(2012)
Adalimumab induces deep remission in patients with Crohn’s disease
Clin Gastroenterol Hepatol
Cited by (0)
Conflicts of interest These authors disclose the following: Guillaume Bouguen has received lecture fees from Abbott Laboratories, Ferring, and MSD Pharma. Barrett G. Levesque is a consultant for Santarus Inc, Prometheus Laboratories, and Castlight Health; and is a member of the speakers bureau for Warner Chilcott, UCB Pharma, Abbott Labs, and Salix. William Sandborn has received consulting fees from ActoGeniX NV, AGI Therapeutics, Inc, Alba Therapeutics Corporation, Albireo, Alfa Wasserman, Amgen, AM-Pharma BV, Anaphore, Astellas Pharma, Athersys, Inc, Atlantic Healthcare Limited, Axcan Pharma (now Aptalis), BioBalance Corporation, Boehringer-Ingelheim, Inc, Bristol Meyers Squibb, Celgene, Celek Pharmaceuticals, Cellerix SL, Cerimon Pharmaceuticals, ChemoCentryx, CoMentis, Cosmo Technologies, Coronado Biosciences, Cytokine Pharmasciences, Eagle Pharmaceuticals, Eisai Medical Research, Inc, Elan Pharmaceuticals, EnGene, Inc, Eli Lilly, Enteromedics, Exagen Diagnostics, Inc, Ferring Pharmaceuticals, Flexion Therapeutics, Inc, Funxional Therapeutics Limited, Genzyme Corporation, Genentech (now Roche), Gilead Sciences, Given Imaging, Glaxo Smith Kline, Human Genome Sciences, Ironwood Pharmaceuticals (previously Microbia, Inc), Janssen (previously Centocor), KaloBios Pharmaceuticals, Inc, Lexicon Pharmaceuticals, Lycera Corporation, Meda Pharmaceuticals (previously Alaven Pharmaceuticals), Merck Research Laboratories, MerckSerono, Millennium Pharmaceuticals (subsequently merged with Takeda), Nisshin Kyorin Pharmaceuticals Co, Ltd, Novo Nordisk A/S, NPS Pharmaceuticals, Optimer Pharmaceuticals, Orexigen Therapeutics, Inc, PDL Biopharma, Pfizer, Procter and Gamble, Prometheus Laboratories, ProtAb Limited, Purgenesis Technologies, Inc, Receptos, Relypsa, Inc, Salient Pharmaceuticals, Salix Pharmaceuticals, Inc, Santarus, Schering Plough Corporation (acquired by Merck), Shire Pharmaceuticals, Sigmoid Pharma Limited, Sirtris Pharmaceuticals, Inc (a Glaxo Smith Kline company), S.L.A. Pharma (UK) Limited, Targacept, Teva Pharmaceuticals, Therakos, Tillotts Pharma AG (acquired by Zeria Pharmaceutical Co, Ltd), TxCell SA, UCB Pharma, Viamet Pharmaceuticals, Vascular Biogenics Limited (VBL), Warner Chilcott UK Limited, Wyeth (now Pfizer); has received lecture fees from Bristol Meyers Squibb and Janssen (previously Centocor); and has received research support from Bristol Meyers Squibb, Genentech, Glaxo Smith Kline, Janssen (previously Centocor), Millennium Pharmaceuticals (now Takeda), Novartis, Pfizer, Procter and Gamble Pharmaceuticals, Shire Pharmaceuticals, and UCB Pharma. The remaining authors disclose no conflicts.